Clinicopathological features and CagA expression in stage IE/IIE1 gastric DLBCL patients who received HPE therapy as a frontline treatment
| Clinicopathological characteristics . | CagA expression . | P* . | |
|---|---|---|---|
| Negative, n = 30 . | Positive, n = 33 . | ||
| Age (median, range), y | 59 (21-87) | 61 (34-88) | .462† |
| Sex, male/female | 12/18 | 12/21 | .767‡ |
| Endoscopic features, n (%) | .771§ | ||
| Gastritis-like or multiple erosion on infiltrative mucosa | 9 (30.0) | 10 (30.3) | |
| Ulceration or ulcerated mass | 16 (53.3) | 19 (57.6) | |
| Erosions on giant nodular folds | 5 (16.7) | 4 (12.1) | |
| Location of tumor(s), n (%) | .062‡ | ||
| Proximal|| or ≥2 components | 14 (46.7) | 8 (24.2) | |
| Distal¶ | 16 (53.3) | 25 (75.8) | |
| Depth of gastric wall involvement, n (%)# | .311‡ | ||
| Submucosa or above | 8/28 (28.6) | 12/29 (41.4) | |
| Muscularis propria or beyond | 20/28 (71.4) | 17/29 (58.6) | |
| Histologic classification | |||
| DLBCL (MALT) | 22 (73.3) | 20 (60.6) | .285‡ |
| “Pure” DLBCL | 8 (26.7) | 13 (39.4) | |
| p-SHP2 expression, n (%)** | <.001‡ | ||
| Negative | 18/24 (75.0) | 7/29 (24.1) | |
| Positive | 6/24 (25.0) | 22/29 (75.9) | |
| p-ERK expression, n (%)** | .002‡ | ||
| Negative | 15/24 (62.5) | 6/29 (20.7) | |
| Positive | 9/24 (37.5) | 23/29 (79.3) | |
| Clinicopathological characteristics . | CagA expression . | P* . | |
|---|---|---|---|
| Negative, n = 30 . | Positive, n = 33 . | ||
| Age (median, range), y | 59 (21-87) | 61 (34-88) | .462† |
| Sex, male/female | 12/18 | 12/21 | .767‡ |
| Endoscopic features, n (%) | .771§ | ||
| Gastritis-like or multiple erosion on infiltrative mucosa | 9 (30.0) | 10 (30.3) | |
| Ulceration or ulcerated mass | 16 (53.3) | 19 (57.6) | |
| Erosions on giant nodular folds | 5 (16.7) | 4 (12.1) | |
| Location of tumor(s), n (%) | .062‡ | ||
| Proximal|| or ≥2 components | 14 (46.7) | 8 (24.2) | |
| Distal¶ | 16 (53.3) | 25 (75.8) | |
| Depth of gastric wall involvement, n (%)# | .311‡ | ||
| Submucosa or above | 8/28 (28.6) | 12/29 (41.4) | |
| Muscularis propria or beyond | 20/28 (71.4) | 17/29 (58.6) | |
| Histologic classification | |||
| DLBCL (MALT) | 22 (73.3) | 20 (60.6) | .285‡ |
| “Pure” DLBCL | 8 (26.7) | 13 (39.4) | |
| p-SHP2 expression, n (%)** | <.001‡ | ||
| Negative | 18/24 (75.0) | 7/29 (24.1) | |
| Positive | 6/24 (25.0) | 22/29 (75.9) | |
| p-ERK expression, n (%)** | .002‡ | ||
| Negative | 15/24 (62.5) | 6/29 (20.7) | |
| Positive | 9/24 (37.5) | 23/29 (79.3) | |
P: Comparison of discrete variables between CagA expression-positive and CagA expression-negative.
P values (2-sided) were calculated using the Student t test.
P values (2-sided) were calculated using the χ2 test or the Fisher exact test.
P values (2-sided) were calculated using 1-way analysis of variance.
Proximal: Middle body, upper body, fundus, or cardia.
Distal: Antrum, angle, or lower body.
Gastric wall involvement was evaluated by endoscopic ultrasonography or computed tomography in 57 patients.
Fifty-three cases with available tissue specimens for assessment of expression patterns of p-SHP-2 and p-ERK by immunohistochemical staining.